Researchers are using artificial intelligence to reduce the dose of a contrast agent that may be left behind in the body after MRI exams, according to a new study. Researchers are using artificial ...

VUEWAY ® injection, a macrocyclic gadolinium-based contrast agent (GBCA), offers effective contrast enhancement at half the gadolinium (Gd) dose (0.05 mmol/kg) compared to other macrocyclic GBCAs for ...

Qualitative ratings showed non-significant differences between the proposed method – a 10% level of gadolinium dose – and acquired full-dose contrast-enhanced MRI images, which was also verified with ...

Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics and safety ...

MENLO PARK, Calif., Oct. 21, 2025 /PRNewswire/ -- Subtle Medical, Inc., a leader in AI-powered medical imaging solutions, today announced positive findings from a proof-of-concept (POC) study with ...

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...

A new study has shown that artificial intelligence could be used to dramatically reduce the amount of gadolinium used in MRI scans. The findings, which are being presented today at the annual meeting ...

The FDA has started a review of a novel MRI contrast agent developed by Bayer that can reduce levels of gadolinium, a rare earth metal that can have damaging health and environmental consequences.